NLS Pharmaceutics (NLS Pharmaceutics) Pre-Tax Income : $-12.17 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. NLS Pharmaceutics's pretax income for the six months ended in Dec. 2023 was $-4.56 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.17 Mil. NLS Pharmaceutics's pretax margin was %.

NLS Pharmaceutics Pre-Tax Income Historical Data

The historical data trend for NLS Pharmaceutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Pre-Tax Income Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-5.45

-2.86

-11.95

-16.50

-12.17

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial								-7.34	-8.64	-7.86	-7.61	-4.56

Competitive Comparison of NLS Pharmaceutics's Pre-Tax Income

For the Biotechnology subindustry, NLS Pharmaceutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Pre-Tax Income falls into.

NLS Pharmaceutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

NLS Pharmaceutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-11.807	+	-0.22	+	-0.145	+	0	+	0
	=	-12.17

NLS Pharmaceutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-4.258	+	-0.157	+	-0.145	+	0	+	0.00099999999999945
	=	-4.56

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-12.17 Mil.

NLS Pharmaceutics (NAS:NLSP) Pre-Tax Income Explanation

NLS Pharmaceutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-4.559	/	0
	=	%

NLS Pharmaceutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.